How GLP-1 Therapy Works: The Science of Weight Loss

What Is GLP-1?

Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone produced by specialised L-cells in the lining of your small intestine. When you eat, these cells release GLP-1 into your bloodstream, where it performs several critical functions related to appetite, digestion, and blood sugar regulation.

GLP-1 belongs to a family of hormones called incretins. The incretin system is your body's built-in mechanism for regulating energy balance -- it helps you feel full after eating, slows digestion so nutrients are absorbed efficiently, and ensures blood sugar levels remain stable.

The Problem: Natural GLP-1 Breaks Down Quickly

Natural GLP-1 has a very short half-life -- approximately 2-3 minutes. An enzyme called dipeptidyl peptidase-4 (DPP-4) rapidly degrades it in the bloodstream. This means the appetite-suppressing and metabolic effects of natural GLP-1 are fleeting. In people with obesity, the incretin system may also be impaired, producing less GLP-1 or having reduced receptor sensitivity.

The Incretin Effect

The "incretin effect" refers to the observation that oral glucose stimulates a much greater insulin response than intravenous glucose -- even when blood sugar levels are identical. This happens because eating triggers the release of incretin hormones (GLP-1 and GIP) from the gut, which amplify the pancreas's insulin response.

GLP-1 (Glucagon-Like Peptide-1)

-- Stimulates insulin release when blood sugar is high
-- Suppresses glucagon (a hormone that raises blood sugar)
-- Slows gastric emptying (prolongs fullness)
-- Acts on brain appetite centres to reduce hunger

GIP (Glucose-Dependent Insulinotropic Polypeptide)

-- Stimulates insulin release (the first incretin discovered)
-- Promotes fat metabolism and energy expenditure
-- Supports bone health and bone mineral density
-- May enhance the effect of GLP-1 when combined

Note: Tirzepatide activates both GLP-1 and GIP receptors (dual agonist).

How Synthetic GLP-1 Mimics the Natural Hormone

GLP-1 receptor agonist medications like semaglutide are synthetic versions of the natural GLP-1 hormone, engineered with critical modifications that make them far more potent and long-lasting than the hormone your body produces.

01

DPP-4 Resistance

The molecular structure of semaglutide has been modified at key positions to resist degradation by the DPP-4 enzyme. While natural GLP-1 lasts only minutes, semaglutide maintains therapeutic levels for approximately 7 days -- enabling once-weekly dosing.

02

Albumin Binding

A fatty acid chain is attached to the semaglutide molecule, which binds to albumin (a protein in blood). This creates a "reservoir" effect -- the drug slowly releases from albumin binding, extending its duration of action and maintaining steady blood levels between weekly doses.

03

Selective Receptor Activation

Despite structural modifications, semaglutide retains high affinity for GLP-1 receptors throughout the body -- in the brain (appetite control), gut (gastric emptying), pancreas (insulin release), and cardiovascular system (protective effects).

In simple terms: Your body makes a signal molecule (GLP-1) that tells your brain "you're full" and tells your pancreas "release insulin." But this signal disappears in minutes. Semaglutide is like a long-lasting version of that same signal, engineered to keep working for an entire week instead of just minutes.

Beyond Weight Loss: Multiple Benefits

Because GLP-1 receptors are found throughout the body, GLP-1 receptor agonists produce beneficial effects across multiple organ systems. Published clinical research has documented improvements in several areas beyond weight reduction.

Benefit Area	Mechanism & Evidence
Weight Loss	Appetite reduction, delayed gastric emptying, and improved food choice behaviour. GLP-1 therapies demonstrate clinically significant weight loss in published trials.
Blood Sugar Control	Glucose-dependent insulin secretion and glucagon suppression. Particularly beneficial for patients with type 2 diabetes or pre-diabetes.
Cardiovascular Health	Reduction in major adverse cardiovascular events (MACE) demonstrated in large-scale outcomes trials. Improvements in blood pressure and lipid profiles.
Liver Health	Reduction in liver fat content in patients with non-alcoholic fatty liver disease (NAFLD). Active clinical trials investigating use in metabolic-associated steatohepatitis (MASH).
Kidney Protection	Evidence suggests protective effects on kidney function, particularly in diabetic patients. Reduced progression of albuminuria documented in clinical research.
Inflammation	Reduction in systemic inflammatory markers (CRP, IL-6). Weight loss itself contributes to reduced chronic inflammation.

Why a Weekly Injection Works

A common question is: how can a single weekly injection produce continuous weight loss effects? The answer lies in semaglutide's pharmacokinetic profile.

Pharmacokinetics

Half-life: Approximately 7 days (168 hours)
Steady state: Reached after 4-5 weeks of weekly dosing
Blood levels: Remain therapeutic throughout the full 7-day period
Absorption: Slow, sustained release from the subcutaneous injection site

Why This Matters for Patients

Convenience: Only one injection per week (vs. daily medications)
Consistency: Stable appetite suppression 24/7, no daily peaks and troughs
Adherence: Weekly dosing is easier to maintain than daily pills
Progressive: Weight loss accumulates with each week of treatment

The Future of GLP-1 Therapy

GLP-1-based therapies are among the fastest-evolving areas in modern medicine. Research is actively exploring several exciting frontiers:

--
Oral formulations: Higher-dose oral semaglutide tablets are in development that may approach the efficacy of injectable formulations, eliminating the need for needles entirely.
--
Triple agonists: Next-generation molecules targeting GLP-1, GIP, and glucagon receptors simultaneously (e.g., retatrutide) are in clinical trials, with early data showing even greater weight loss potential.
--
Expanded indications: Clinical trials are investigating GLP-1 therapies for metabolic liver disease (MASH), sleep apnoea, chronic kidney disease, Parkinson's disease, and addiction.
--
Combination therapies: Pairing GLP-1 agonists with other medications (e.g., amylin analogues) may enhance weight loss outcomes beyond what either drug achieves alone.

References

Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439. PMID: 17928588
Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20 Suppl 1:5-21. PMID: 29364588
Muller TD, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. PMID: 31767182
Lau J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. PMID: 26308095
Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight. Diabetes Obes Metab. 2017;19(9):1242-1251. PMID: 28266779
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131
Newsome PN, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID: 33185364
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526. PMID: 37385337
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185

Medical Review

This article was reviewed by the Semaglutide.ng team for scientific accuracy. Content is based on published peer-reviewed research in endocrinology and pharmacology. It is intended for educational purposes only and does not constitute medical advice.

Last reviewed: February 2026

How GLP-1 Therapy Works